Intravitreal bevacizumab combined with photodynamic therapy for the treatment of occult choroidal neovascularization associated with serous pigment epithelium detachment in age-related macular degeneration

Retina

Volumn 27, Issue 7, 2007, Pages 891-896

  Ladas, Ioannis D ^a,c   Kotsolis, Athanasios I ^a   Papakostas, Thanos D ^a   Rouvas, Alexandros A ^a   Karagiannis, Dimitrios A ^b   Vergados, Ioannis ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b B Department   (Greece)

^c NONE   (Greece)

Author keywords

Age related macular degeneration; Bevacizumab; Occult choroidal neovascularization; Photodynamic therapy; Serous pigment epithelium detachment

Indexed keywords

BEVACIZUMAB;

ADULT; ARTICLE; CONTROLLED STUDY; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; OPTICAL COHERENCE TOMOGRAPHY; PHOTODYNAMIC THERAPY; PIGMENT EPITHELIUM; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; RETROSPECTIVE STUDY; SUBRETINAL FLUID; SUBRETINAL NEOVASCULARIZATION; THICKNESS; TREATMENT DURATION; VISUAL ACUITY;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CHOROIDAL NEOVASCULARIZATION; DRUG THERAPY, COMBINATION; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; INJECTIONS; MACULAR DEGENERATION; MALE; MIDDLE AGED; PHOTOCHEMOTHERAPY; PIGMENT EPITHELIUM OF EYE; RETINAL DETACHMENT; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VITREOUS BODY;

EID: 34748915804     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e3180ca9ad9     Document Type: Article

References (21)

1. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials - TAP Report. Arch Ophthalmol 1999;117:1329-1345.
2. Bressler NM. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group: Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: twoyear results of 2 randomized clinical trials-TAP report 2. Arch Ophthalmol 2001;119:198-207.
3. Verteporfin in Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization - Verteporfin in Photodynamic Therapy Report 2. Am J Ophthalmol 2001;131:541-560.
4. Slakter JS, Yannuzzi LA, Sorenson JA, et al. A pilot study of indocyanine green videoangiography-guided laser photocoagulation treatment of occult choroidal neovascularization in age-related macular degeneration. Arch Ophthalmol 1994;112:465-472.
5. Lim JI, Aaberg TM, Capone A Jr, Sternberg P Jr. Indocyanine green angiography-guided photocoagulation of choroidal neovascularization associated with retinal pigment epithelial detachment. Am J Ophthalmol 1997;123:524-532.
6. Brancato R, Introini U, Bolognesi G, et al. ICGA-guided laser photocoagulation of occult choroidal neovascularization in age-related macular degeneration. Indocyanine green angiography. Retina 2000;20:134-142.
7. Axer-Siegel R, Ehrlich R, Roseublatt I, et al. Photodynamic therapy for occult choroidal neovascularization with pigment epithelium detachment in age-related macular degeneration. Arch Ophthalmol 2004;122:453-459.
8. Ladas ID, Kotsolis AI, Rouvas AA, et al. Efficacy of photodynamic therapy in the management of occult choroidal neovascularization associated with serous pigment epithelium detachment. Ophthalmologica 2007 (in press).
9. Rosenfeld PJ, Brown DM, Heier JS, et al, MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431.
10. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342.
11. Moshfeghi AA, Rosenfeld PJ, Puliafito CA, et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open-label clinical study. Ophthalmology 2006;113:2002.e1-12.
12. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005;36:331-335.
13. Avery RL, Pieramici DJ, Rabena MD, et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006;113:363-372.e5.
14. Spaide RF, Laud K, Fine HF, et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 2006;26:383-390.
15. Rich RM, Rosenfeld PJ, Puliafito CA, et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 2006;26:495-511.
16. Bashshur ZF, Bazarbachi A, Schakal A, et al. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 2006;142:1-9.
17. Jonas JB, Harder B, Spandau UH, et al. Bevacizumab for occult subfoveal neovascularization in age-related macular degeneration. Eur J Ophthalmol 2006;16:774-775.
18. Lazic R, Gabric N. Intravitreally administered bevacizumab (Avastin) in minimally classic and occult choroidal neovascularization secondary to age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2006;245:68-73.
19. Aggio FB, Melo GB, Hofling-Lima AL, Eid FM. Photodynamic therapy with verteporfin combined with intravitreal injection for exudative age-related macular degeneration. Acta Ophthalmol Scand 2006;84:831-833.
20. Heier JS, Boyer DS, Ciulla TA, et al. Ranibizumab combined with verteporfin photodynamic therapy in neovascular agerelated macular degeneration: year 1 results of the FOCUS study. Arch Ophthalmol 2006;124:1532-1542.
21. Spaide RF. Rationale for combination therapies for choroidal neovascularization. Am J Ophthalmol 2006;141:149-156.